WallStSmart

IQVIA Holdings Inc (IQV)vsiSpecimen Inc (ISPC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 486374% more annual revenue ($16.31B vs $3.35M). IQV leads profitability with a 8.3% profit margin vs 0.0%. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

ISPC

Avoid

33

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -14.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Intrinsic value data unavailable for ISPC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

ISPC2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

ISPC4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.92M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : ISPC

The strongest argument for ISPC centers on Price/Book, Debt/Equity.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : ISPC

The primary concerns for ISPC are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ISPC carries more volatility with a beta of 1.88 — expect wider price swings.

IQV is growing revenue faster at 10.3% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IQV scores higher overall (72/100 vs 33/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

iSpecimen Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

iSpecimen, Inc. provides technology that connects life science researchers in need of human biofluids, tissues and living cells for their research with biospecimens available from healthcare provider organizations globally. The company is headquartered in Lexington, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?